Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells in vitro, there is now more scope to explore basic immune cell biology coupled with the search for new therapeutics.
A new path to the clinic using CRISPR-Cas screens and cell panel drug screens in target ID and validation, is hosted by DDW and supported by Horizon Discovery. It features the expertise of Palwinder Mander, GSK.
It took place on 6 July 2021. Watch on demand for FREE here.
In this webinar, given by Palwinder Mander from the Immuno-Epigenetics, Adaptive Immunity Research Unit, GSK, Stevenage, UK you will hear how pooled CRISPR-Cas screens combined with target validation using existing drugs can lead to the rapid translation of targets towards the clinic. This webinar will also illustrate how validation of targets in primary immune cells from screens carried our in immune cell lines can help to prioritise the most robust targets.
